| 1 | business development and corporate | | | | | | | 2 | 0.19% |
| 2 | immune cells such as | | | | | | | 2 | 0.19% |
| 3 | in early 2021 close | | | | | | | 2 | 0.19% |
| 4 | than 20 years of | | | | | | | 2 | 0.19% |
| 5 | elpis biopharmaceuticals home about | | | | | | | 1 | 0.09% |
| 6 | antibody and t cell | | | | | | | 1 | 0.09% |
| 7 | their cancer cells car | | | | | | | 1 | 0.09% |
| 8 | cancer cells car chimeric | | | | | | | 1 | 0.09% |
| 9 | antigen receptort cells are | | | | | | | 1 | 0.09% |
| 10 | receptort cells are tcells | | | | | | | 1 | 0.09% |
| 11 | cells are tcells engineered | | | | | | | 1 | 0.09% |
| 12 | are tcells engineered with | | | | | | | 1 | 0.09% |
| 13 | tcells engineered with a | | | | | | | 1 | 0.09% |
| 14 | engineered with a tumor | | | | | | | 1 | 0.09% |
| 15 | with a tumor specific | | | | | | | 1 | 0.09% |
| 16 | t cell signaling domains | | | | | | | 1 | 0.09% |
| 17 | and t cell signaling | | | | | | | 1 | 0.09% |
| 18 | fight against their cancer | | | | | | | 1 | 0.09% |
| 19 | cell signaling domains to | | | | | | | 1 | 0.09% |
| 20 | signaling domains to enable | | | | | | | 1 | 0.09% |
| 21 | domains to enable a | | | | | | | 1 | 0.09% |
| 22 | to enable a specific | | | | | | | 1 | 0.09% |
| 23 | enable a specific engagement | | | | | | | 1 | 0.09% |
| 24 | of immune cells to | | | | | | | 1 | 0.09% |
| 25 | immune cells to the | | | | | | | 1 | 0.09% |
| 26 | cells to the cancer | | | | | | | 1 | 0.09% |
| 27 | to the cancer cells | | | | | | | 1 | 0.09% |
| 28 | the cancer cells while | | | | | | | 1 | 0.09% |
| 29 | against their cancer cells | | | | | | | 1 | 0.09% |
| 30 | engineered to fight against | | | | | | | 1 | 0.09% |
| 31 | to fight against their | | | | | | | 1 | 0.09% |
| 32 | dual targeting cart adoptive | | | | | | | 1 | 0.09% |
| 33 | killing efficacy we plan | | | | | | | 1 | 0.09% |
| 34 | efficacy we plan to | | | | | | | 1 | 0.09% |
| 35 | we plan to advance | | | | | | | 1 | 0.09% |
| 36 | plan to advance epim001 | | | | | | | 1 | 0.09% |
| 37 | to advance epim001 to | | | | | | | 1 | 0.09% |
| 38 | advance epim001 to clinical | | | | | | | 1 | 0.09% |
| 39 | epim001 to clinical studies | | | | | | | 1 | 0.09% |
| 40 | early 2021 close dual | | | | | | | 1 | 0.09% |